rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease
Enrolling by invitation · NCT04833907 · Registry updated 2025-11-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Canavan disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Central Nervous System Demyelinating Diseases, Leukoencephalopathies, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, demyelinating disease, hereditary disease, inborn errors of metabolism, inherited neurodegenerative disorder, metabolic disease, nervous system disorder, neurodegenerative disease | Enrolling by invitation | Phase 1 / Phase 2 | 2025-11-14 | NCT04833907 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Myrtelle Inc. | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dayton Children's Hospital | Dayton | United States | 75 |